Pexip Infinity. A scalable meeting platform providing personal meeting rooms for any number of users on video, voice and mobile. A fully distributed architecture allowing global enterprises and service providers so host large meetings while saving WAN bandwidth usage. Fully interoperable with industry standard endpoints using SIP and H.323. Works equally well with Microsoft(R) Lync(R) clients using H.264SVC, and with WebRTC-capable browsers.

As a idea factory, incubator and investor, Askeladden & Co identifies opportunities, develop concepts and scale up companies. Our sweet-spot is in traditional industries that - until now - have seen limited consolidation, limited innovation, too high prices and a customer journey that has been standing still since the 90s.   Our investments and startup journeys so far:  Cutters | Adams Matkasse | Freska | Lotel | Lorry Restaurant | Wellbee

Wonderloop is video-identity of people with goal of a new way of distributing wealth in the world. For users it´s social video-profiles of people. Wonderloop is a tool, more than a social network in itself. We want to drive traffic to social networks based on new connections made. It's the step before social networking. It's the step before everything. With Wonderloop, we wish to change the culture of human identity and with that change the way we connect and give - directly to people.

Bio-Me Is Setting The Standard For Routine Microbiome Analysis Gut microbiome research has become essential to almost every medical research field. Next-generation sequencing (NGS) technologies have been crucial in enabling a breakthrough in our understanding of the significant role gut microbes play in health and disease. However, the field is now moving past the exploratory research phase and there is a need to translate microbiome research findings into actionable clinical solutions. Application of NGS for this purpose faces several challenges related to precision, turnaround time, cost per sample, and the need for complex bioinformatic pipelines. Our mission is to provide researchers and industry with a qPCR-based analysis service that delivers actionable microbiome results.

Availy, founded in 2021, is a disruptive technology player specializing in resource management and booking solutions. We have established strategic partnerships with key players like ExtendaGO and Zettle by PayPal, reinforcing our growth in the European market. Our platform is scalable across industries and locations, with a clear objective: to become a global leader in resource optimization. Availy provides a digital B2B platform that combines intelligent resource optimization with a seamless booking experience. The platform is designed for the hair and wellness industries in Norway and Europe, delivering a clear value proposition that includes: - Efficient Resource Management: Optimize scheduling of staff, equipment, and facilities, achieving up to 30% increased efficiency and resource utilization. - Increased Profitability: Maximize the use of company resources to achieve measurable productivity gains and higher earnings. - Seamless Customer Experiences: User-friendly booking integrated into the company's own channels. - Open API Technology/Partner Strategy: Cloud-based API technology enabling collaboration and shared customer journeys with other SaaS solutions (CRM, web, POS, etc.). Our goal is to become a leader in resource management and booking, supported by partnerships with recognized providers of POS, CRM, payment solutions and accounting. This ensures technical excellence, cost-effective solutions, and the distribution power to scale the platform effectively.

We are in indie game developer based out of Oslo, Norway. We have to date launched five games for PC, Switch and mobile platforms. At the moment we develop "Life Below", a creative strategy city-builder where you build and manage ocean ecosystems. So a reef builder! In addition to our own IP, we develop games and gamification projects for society. We call ourselves an impact game developer as many of our projects are focused on positive change to society. Right now we develop a game for all kids going into hospital, a history game to spice up history learning in schools, a city cleaning game using the mascot of Oslo, a climate game and an awareness game tackling difficult issues in relation to sex and identify. Many of our impact projects are successes, and are widely used. Our aim is to make society better, one game at the time.

Our mission is to help food manufacturers reduce food waste and cost through our digital platform. To date, we've successfully transacted over 4.000 tons of food, and we're continuing to scale our business to have an even greater impact. We have ambitious growth plans and are expanding. We recently carried out a rebranding and are in the process of building our product & technology team to scale further.

Niuton is a deep tech platform that works on autonomous and decentralized solutions based on Newtonian principles and our end customers are hedge funds. Currently, we have a team of five people, the tech dev and research stretches three years back and we have been with one year live with clients. Now we are looking for a senior python specialist to automate the data flow in and out of our core machinery. The data feed into Niutons machinery is from Twelvedata and the output is clients around the world. For the right candidate, we can consider offering 0.5% of shares equity (valuation right now 7.5 million USD), you will be assisted by our other senior python specialist that handles the core machinery itself. The expected duration of this assignment is three to four months ONLY. Start date 1. January 2022. Resources have to be available 100% of the time during the assignment, most preferably in Oslo. The MVP is ready, Niuton is now exactly what we want, and the success criterion is achieving 99% uptime on a day-to-day basis.

Vi er Nolo Nordic og vi gjør alkoholfritt mer spennende, sofistikert, gøy og smakfullt ved å produsere førsteklasses drikkevarer under merkenavnene ALT. og Ambijus. Akkurat nå brygger vi nye nettsider, men besøk gjerne linkene over for å lære mer om våre prisvinnende og kompromissløse alkoholfrie drikker.

50% of the population will encounter mental illness, but 65% leave treatment without results. We're here to change that. We develop the world's first holistic mental healthcare platform designed to improve the effectiveness of psychological treatment. Our SaaS platform for psychologists combines the basic tools needed to administer a private practice, with novel research-based treatment instruments. We are an ambitious team of psychology specialists, business developers, and an advisory board with industry specialists. You can take a look at our team [here](https://www.konfidens.no/team). Mindcare is backed by Innovation Norway, Aleap, and several private investors. We are now hiring our first team members. We're looking for two talented developers to join our company as co-founders and help build the organization and product. Is this you or someone you know? Get in touch!

We digitize our customers by supporting more business processes with software. The core drivers are better insight and higher consistency. We make use of or create new software that solve each prospect. We are profitable and are looking to expand our offering with a modern platform. Voit offers IT systems that make less use of data with experience from everyday life, production and startups.

Bile duct cancer is an aggressive form of cancer with an extremely poor overall five-year survival rate of just 2-5 %. Classified as an orphan disease, annual incidence in Europe and the United States of 15-22,000 patients, and a significantly higher incidence in Asia, makes it a major player and the deadliest of the gastrointestinal cancers. Only a small number of patients are eligible for a complete surgical resection by local resection or liver transplantation, and more than 50% of these relapse. The vast majority are treated by gemcitabine-based palliative chemotherapy with a life expectancy of 11 months, and five-year survival rate of zero %. Thus, there is an urgent and unmet medical need to develop new and better treatment strategies for these patients. The innovations developed by Seald are a result of adopting a multidisciplinary approach to the diagnosis and treatment of bile duct cancer, based on extensive drug sensitivity assays on living cancer cells, molecular biomarkers, DNA sequencing, extensive bioinformatics analyses and zebrafish models. Sealds’s holistic approach is unique with possible modes of action that can be used on other solid cancers. Our technology includes drug repurposing and innovation on new medical substances, diagnostics and methodology. The stipulated pharma market globally is USD 2.1-4.2 billion, in addition to the markets for diagnostics and platform technology

RESPINOR is a privately-owned medical device company, founded in Oslo, 2015. We have developed an objective measure of breathing for critically ill patients within intensive care. The technology provides precise, continuous and real-time information of diaphragm function, our main breathing muscle, to increase the quality of care and reducing costs. RESPINOR’s technology is the winner of Horizon 2020 both in phase I and II. We are addressing an unmet medical need because every breath counts.

New drugs for treating diseases of Down syndrome. More than 1% of the global GDP is spent on nursing demented people, and the number requiring nursing will triple within 2050. The disease is progressive, leading to death. There is no current cure available, only symptomatic treatments. Individuals born with Down syndrome have a more than 10x risk of developing dementia as well as a host of other diseases including diabetes. Our drug target, DYRK1A is an enzyme found on chromosome 21, and is considered a key factor determining developmental and medical challenges faced by individuals with Down. The enzyme interacts with multiple biological mechanisms involved in Alzheimer’s and autoimmune diseases. Advanced drug designUsing advanced drug design technologies, we have designed a potent DYRK1A inhibitor drug, PST-900. A use and substance of matter patent have been applied for. The company is currently working on chemical Lead Optimisation with 8 full-time medicinal chemists contracted.Financing and milestonesThe Company raised NOK 5 million in 2015 and 8.8 MNOK in 2016/2017, matching non-dilutive research (BIA) and business grants (Innovation Norway). We demonstrated Proof of Principle in a model system for Alzheimer’s disease in 2Q2016. We have also demonstrated that our drug is capable of reversing diabetes in an animal model. Together with clinical and regulatory advisors, we have identified an important unmet need for a drug to treat newly diagnosed diabetes. We will use this indication to quickly progress to market and from there develop analogous drug molecules in Alzheimer’s disease, focused especially in Down syndrome. Funding soughtThe current funding round will raise 15+ MNOK to fund the progression to the final Development Candidate during 2018. Following this, further funding will be sought to perform toxicology/safety and Phase 1 clinical studies. A highly experienced teamThe team behind Pharmasum Therapeutics have broad, international pharmaceutical and biotechnology experience, and is supported by an excellent group of advisors. Anders Fugelli, Ph.D., CEO. John Sigurd Svendsen, Ph.D., CSO. Pauline Stewart-Long, Ph.D. Project Management. Henning Mork, CFO. Board of Directors: Andrew Parsons, PhD. Øystein Soug, MSc. Mark Treherne, PhD, John Sigurd Svendsen, PhD.

BusinessClass.com is a sophisticated travel tech startup. Our vision is to become the global leader in premium travel by offering the best travel search, the best travel offers, as well as world-class reviews and other inspirational content. BusinessClass.com is targeting the more quality-minded travellers who want the best travel products at the best possible prices. BusinessClass.com is suitable for both corporate & leisure travel, offering top-quality airline tickets and accommodation. The team and advisers at BusinessClass.com have extensive travel tech industry knowledge. Founder Jason Eckhoff was EY Entrepreneur Of The Year in 2013 when his first online travel company had beaten 28.000 growth companies over a 4-year period. BusinessClass.com is (other than the founder/CEO) backed by a former C-level manager of a major airline and a co-founder of a unicorn (a company valued at more than 1 USD billion). We are currently considering raising additional risk capital for further developing BusinessClass.com and creating the world's best search engine for premium travel!